With theadvancementof the study of molecularbiology, the research of the molecular targeteddrugssuch asEGFRinhibitor and VEGFinhibitor, become one of the hot spots.
Because the underlying biology is so clear, it is far more likely that the PCSK9 inhibitor Sanofi is developing with partner Regeneron will prove helpful to heart patients.